Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2016', provides in depth analysis on P2X Purinoceptor 3 (P2RX3) targeted pipeline therapeutics. The report provides comprehensive information on the P2X Purinoceptor 3 (P2RX3) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 3 (P2RX3) - The report reviews P2X Purinoceptor 3 (P2RX3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics and enlists all their major and minor projects - The report assesses P2X Purinoceptor 3 (P2RX3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to P2X Purinoceptor 3 (P2RX3) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 3 (P2RX3) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 3 (P2RX3) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 P2X Purinoceptor 3 (P2RX3) Overview 7 Therapeutics Development 8 P2X Purinoceptor 3 (P2RX3) - Products under Development by Stage of Development 8 P2X Purinoceptor 3 (P2RX3) - Products under Development by Therapy Area 9 P2X Purinoceptor 3 (P2RX3) - Products under Development by Indication 10 P2X Purinoceptor 3 (P2RX3) - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 P2X Purinoceptor 3 (P2RX3) - Products under Development by Companies 14 P2X Purinoceptor 3 (P2RX3) - Products under Development by Universities/Institutes 16 P2X Purinoceptor 3 (P2RX3) - Therapeutics Assessment 18 Assessment by Monotherapy/Combination Products 18 Assessment by Mechanism of Action 19 Assessment by Route of Administration 20 Assessment by Molecule Type 21 P2X Purinoceptor 3 (P2RX3) - Companies Involved in Therapeutics Development 23 Afferent Pharmaceuticals, Inc. 23 Asana BioSciences, LLC 24 Bayer AG 25 Integral Molecular, Inc. 26 Neurim Pharmaceuticals Ltd 27 Pfizer Inc. 28 Shionogi & Co., Ltd. 29 P2X Purinoceptor 3 (P2RX3) - Drug Profiles 30 AF-130 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 AF-219 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 ASN-009 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Drug to Antagonize P2X3 for Endometriosis - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Monoclonal Antibodies to Antagonize P2X3 Receptor for Pain - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Monoclonal Antibody to Antagonize P2X2 and P2X3 for Visceral Pain - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 NEO-5937 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 OSX-300 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 OSX-300 Backups - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 piromelatine - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Small Molecule to Antagonize P2X3 Receptor for Neuropathic Pain - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 P2X Purinoceptor 3 (P2RX3) - Dormant Projects 45 P2X Purinoceptor 3 (P2RX3) - Discontinued Products 47 P2X Purinoceptor 3 (P2RX3) - Featured News & Press Releases 48 Sep 28, 2016: Neurim Pharmaceuticals Announces First Patients Enrollments in ReCOGNITION - Phase II Clinical Trial of Piromelatine for Mild Alzheimers Disease 48 Sep 05, 2016: Hypertension: releasing the pressure at its source 48 May 18, 2016: Afferent Pharmaceuticals Reports Cardiovascular Research Showing P2X3 Antagonism Successfully Reduces Hypertension By Restoring Autonomic Nervous Balance at the 2016 American Thoracic Society Conference 50 May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference 51 Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Chronic Cough Clinical Data at the Upcoming American Thoracic Society 2016 International Conference 53 Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Hypertension Research at the Upcoming American Thoracic Society 2016 International Conference 54 Dec 08, 2015: Afferent Pharmaceuticals Advances Novel Molecule, AF-130, to Phase 1 Clinical Trial 54 Nov 11, 2015: Afferent Pharmaceuticals Announces Phase 2 Clinical Trial with AF-219 in Cough in Idiopathic Pulmonary Fibrosis (IPF) Patients 55 Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial 55 Feb 26, 2015: Afferent Clinical Data for Lead Candidate, AF-219, Demonstrate Improvements in Pain and Urinary Urgency in Interstitial Cystitis / Bladder Pain Syndrome 56 Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet 57 Sep 09, 2013: Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company's Lead P2X3 Antagonist, AF-219 58 Feb 18, 2013: Neurim Pharma Announces Positive Phase II Clinical Trial Results Of Piromelatine For Treatment Of Insomnia 59 Jul 24, 2011: Neurim Announces Positive Results From Phase I And Phase Ib Clinical Trials With Neu-P11 60 Aug 25, 2010: Afferent Reports Data Supporting Potential Utility Of P2X3 Antagonists In Lowering Bladder Reflexes 61 Appendix 62 Methodology 62 Coverage 62 Secondary Research 62 Primary Research 62 Expert Panel Validation 62 Contact Us 62 Disclaimer 63
List of Tables
Number of Products under Development for, H2 2016 8 Number of Products under Development by Therapy Area, H2 2016 9 Number of Products under Development by Indication, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Early Stage Products, H2 2016 13 Number of Products under Development by Companies, H2 2016 14 Products under Development by Companies, H2 2016 15 Number of Products under Investigation by Universities/Institutes, H2 2016 16 Products under Investigation by Universities/Institutes, H2 2016 17 Assessment by Monotherapy/Combination Products, H2 2016 18 Number of Products by Stage and Mechanism of Action, H2 2016 19 Number of Products by Stage and Route of Administration, H2 2016 20 Number of Products by Stage and Molecule Type, H2 2016 22 Pipeline by Afferent Pharmaceuticals, Inc., H2 2016 23 Pipeline by Asana BioSciences, LLC, H2 2016 24 Pipeline by Bayer AG, H2 2016 25 Pipeline by Integral Molecular, Inc., H2 2016 26 Pipeline by Neurim Pharmaceuticals Ltd, H2 2016 27 Pipeline by Pfizer Inc., H2 2016 28 Pipeline by Shionogi & Co., Ltd., H2 2016 29 Dormant Projects, H2 2016 45 Dormant Projects (Contd..1), H2 2016 46 Discontinued Products, H2 2016 47
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
